NDATOPICALSOLUTION
Approved
Jul 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
8
Data completeness
5/8 — Partial
YCANTH (cantharidin) by Verrica Pharmaceuticals. Approved for molluscum contagiosum, warts. First approved in 2023.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YCANTH (cantharidin) is a topical solution approved for molluscum contagiosum and warts, representing the first FDA-approved formulation of cantharidin for these indications. The drug works via direct application to lesions, inducing a blister response that facilitates removal of viral lesions. It addresses a significant unmet need in dermatology with a simple, office-based treatment paradigm.
Growth14.8 years to LOE
Early-stage growth trajectory with modest competitive pressure suggests expanding field team and brand-building investment over next 3-5 years.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (2)
Clinical Trials (8)
Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)
Started Mar 2026
600 enrolled
Common Warts (Verruca Vulgaris)Common WartsHuman Papilloma Virus (HPV)+1 more
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
Started Dec 2025
300 enrolled
Common WartsCommon Warts (Verruca Vulgaris)Human Papilloma Virus (HPV)+1 more
Cantharidin and Occlusion in Verruca Epithelium
Started Mar 2018
56 enrolled
Common WartWarts HandWarts+9 more
Cantharidin Application in Molluscum Patients-1
Started Mar 2018
266 enrolled
Molluscum Contagiosum
Cantharidin Application in Molluscum Patients
Started Feb 2018
262 enrolled
Molluscum Contagiosum
Worked on YCANTH at Verrica Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.